Anti-CD40 Antibody Formulation Viscosity and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for pharmaceutical formulations that effectively prepare and administer antibodies targeting the CD40/CD154 interaction for immune system suppression, particularly in organ transplantation and autoimmune disorder treatments.
Innovation Solution
A pharmaceutical composition containing 200 mg/mL of an anti-CD40 antibody with specific amino acid sequences for the heavy and light chains, formulated with polysorbate 20, sodium acetate, arginine, glutamate, and a pH of 5.4, suitable for intravenous or subcutaneous injection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high concentration of anti-CD40 antibody (200 mg/mL) is formulated, then productivity and dosage efficiency are improved, but aggregation and stability issues worsen
Solution Approach 1:
The patent changes multiple formulation parameters including pH (optimized to 5.4), ionic strength, and excipient concentrations to stabilize the antibody at 200 mg/mL concentration. This resolves the contradiction by adjusting physical-chemical parameters to prevent aggregation while maintaining high concentration for improved productivity
Solution Approach 2:
The patent introduces excipients (polysorbate 20, arginine, glutamate, sodium acetate) as intermediary substances that mediate between the high concentration antibody and the formulation environment. These intermediaries prevent aggregation and maintain stability, allowing high concentration formulation without compromising reliability
2Quantity of substance
If high concentration of anti-CD40 antibody (200 mg/mL) is formulated, then viscosity increases which improves injection volume efficiency, but injectability and ease of operation worsen
Solution Approach 1:
The patent optimizes pH to 5.4 and adjusts ionic strength through specific excipient concentrations to control the viscosity profile. This resolves the contradiction by finding the optimal parameter range where sufficient concentration is achieved while viscosity remains manageable for injection
Solution Approach 2:
The patent uses polysorbate 20 as a surface-active excipient that locally modifies the interface properties and reduces intermolecular interactions at high concentration. This local quality modification prevents excessive viscosity increase while maintaining high antibody concentration for injection volume efficiency
3Duration of action of stationary object
If extended shelf-life is achieved through optimized formulation, then reliability improves, but formulation complexity and manufacturing difficulty increase
Solution Approach 1:
The patent establishes specific parameter ranges (pH 5.4, defined excipient concentrations) that simultaneously achieve extended shelf-life and maintain manufacturability. By optimizing these parameters, the formulation achieves stability without excessive complexity in manufacturing processes
4Reliability
If monomeric form stability is enhanced, then antibody efficacy improves, but aggregation control requirements increase formulation complexity
Solution Approach 1:
The patent employs multiple excipients (polysorbate 20, arginine, glutamate) as intermediary substances that specifically interact with the antibody to prevent aggregation and maintain monomeric form. These intermediaries simplify the overall formulation approach by using well-characterized stabilizing agents rather than complex formulation strategies
Data Source
AI summary
The present disclosure features a pharmaceutical formulation containing an anti-CD40 antibody, KPL-404.